BMS’ Opdivo Bests Pfizer’s Adcetris in Late-Stage Hodgkin’s Lymphoma Study
Bristol Myers Squibb’s Opdivo leads to better survival outcomes in patients with stage 3 or 4 newly diagnosed Hodgkin’s lymphoma, compared with Pfizer and Seagen’s antibody-drug conjugate Adcetris, according to late-stage results published Wednesday in The …